Fujifilm expands its healthcare footprint with $800M acquisition of cell-culture manufacturers

Fujifilm continues to expand its healthcare footprint with the recent acquisition of a pair of cell culture media units from Japan’s JXTG Holdings for about $800 million. The photography and imaging company, which has said it plans to be a major player in the healthcare sector, by June expects to complete the purchase of all outstanding shares of JXTG’s two companies—Irvine Scientific Sales based in California and IS Japan. Culture medium is a solid, liquid or semi-solid designed to support the growth of microorganisms or cells.  Both Irvine Scientific and IS produce a variety of products including culture media for biopharmaceutical production, in vitro fertilization and cell therapy.